Abstract:Liver injury is an important consideration of these drugs. Prognosis with supportive care is good, with normalisation of liver biochemistry the most likely outcome, although hospitalisation may be required and, rarely, liver transplantation. A detailed drug and dietary supplement history is important in elucidating causes of DILI. Summary Background Reports of DILI due to herbal and dietary supplements have been increasing over time. Aims To characterise clinical, laboratory and histopathological phenotypes and outcomes of drug‐induced liver injury (DILI) due to anabolic‐androgenic steroids (AAS), selective androgen receptor modulators (SARMs), and bodybuilding supplements (BBS) in Australia. Methods Retrospective case series. Patients presented to nine Australian tertiary hospitals, 2017–2023. DILI was defined biochemically and patients were included if their treating physician attributed DILI to preceding use of AAS, SARMs or BBS. Primary endpoint was time to normalisation of liver biochemistry. Secondary endpoints were hospitalisation for investigation or management of DILI, death attributable to liver injury, and liver transplantation. Results Twenty‐three cases of DILI were identified, involving 40 drugs: 18 AAS, 14 SARMs and eight BBS. Patients were predominantly male (22/23), with median age 30 years (IQR 26–42). Most were symptomatic (21/23). Median latency of onset was 58 days (IQR 28–112 days) from drug commencement. Most patients (17/23) were admitted to hospital. Based on updated Roussel Uclaf Causality Assessment Method, DILI was possible in 17/23, probable in 2/23 and unlikely in 4/23. Median time to normalisation of liver biochemistry was 175 days (IQR 70–292 days) from presentation. Three (3/23) were treated with corticosteroids, 14/23 were treated for itch, and one (1/23) underwent liver transplantation. There were no deaths. Conclusions The prognosis of DILI from AAS, SARMs and BBS is good although liver transplantation may rarely be required. A detailed drug history is important in uncovering DILI due to these supplements.

S4244 Acute Hepatocellular Injury Induced by Pre-Workout Supplements

S4554 Falling Through The Cracks: A Case Of Cholestatic Injury With Supratherapeutic Testosterone Supplementation

Crushing Muscles: A Case Study on Rhabdomyolysis, Renal Failure, and Compartment Syndrome Triggered by Pre-Workout Supplement Abuse

Underreporting Supplements: A Case of Drug-induced Liver Injury Due to a Testosterone Booster

Acute Liver Injury After Long-Term Herbal "Liver Cleansing" and "Sleep Aid" Supplement Use

LIVER INJURY INDUCED BY HERBAL AND DIETARY SUPPLEMENTS: A POOLED ANALYSIS OF CASE REPORTS

Drug-induced liver injury and anti-hepatotoxic effect of herbal compounds: a metabolic mechanism perspective

A unusual presentation of liver failure caused by Ibuprofen-sustained release capsules: A case report

A new prognostic model for drug-induced liver injury especially suitable for Chinese population

S4397 Drug-Induced Liver Injury Secondary to Recent Ozempic use

S4443 A Case of Drug-Induced Liver Injury Caused by Mushroom Gummy Ingestion

Drug‐induced liver injury from selective androgen receptor modulators, anabolic‐androgenic steroids and bodybuilding supplements in Australia

S4684 Rare Case of Drug-Induced Liver Injury Secondary to Benadryl Use

Management of Acute Hepatotoxicity Including Medical Agents and Liver Support Systems

Herbal and Dietary Supplement-Induced Liver Injury: A Nationwide Comparative Study

S4241 Attack of the Maca: Drug-Induced Liver Injury Secondary to Lepidium meyenii

Cholestatic liver injury associated with dietary supplements: a report of five cases in active duty service members

S4269 A K(NAC)K for DILI

Idiosyncratic drug-induced liver injury related to use of novel selective androgen receptor modulator RAD140 (Testalone): a case report

Severe Drug-Induced Liver Injury From Over-the-Counter Medication

Therapeutic Potential of Nutraceuticals against Drug-Induced Liver Injury